Hydration Requirements with Emetogenic Chemotherapy: Granisetron Extended-Release Subcutaneous Versus Palonosetron

References

• Bloechl-Daum B , DeusonRR, MavrosP, HansenM, HerrstedtJ. Delayed nausea and vomiting continue to reduce patients’ quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment. J. Clin. Oncol.24(27), 4472–4478 (2006).
   PubMed Web of Science ®Google Scholar
• Cohen L , De MoorCA, EisenbergP, MingEE, HuH. Chemotherapy-induced nausea and vomiting: incidence and impact on patient quality of life at community oncology settings. Support. Care Cancer15(5), 497–503 (2007).
   PubMed Web of Science ®Google Scholar
• Haiderali A , MendittoL, GoodM, TeitelbaumA, WegnerJ. Impact on daily functioning and indirect/direct costs associated with chemotherapy-induced nausea and vomiting (CINV) in a U.S. population. Support. Care Cancer19(6), 843–851 (2011).
   PubMed Web of Science ®Google Scholar
• Van Laar ES , DesaiJM, JatoiA. Professional educational needs for chemotherapy-induced nausea and vomiting (CINV): multinational survey results from 2388 health care providers. Support. Care Cancer23(1), 151–157 (2015).
   PubMed Web of Science ®Google Scholar
• Hilarius DL , KloegPH, Van Der WallE, Van Den HeuvelJJ, GundyCM, AaronsonNK. Chemotherapy-induced nausea and vomiting in daily clinical practice: a community hospital-based study. Support. Care Cancer20(1), 107–117 (2012).
   PubMed Web of Science ®Google Scholar
• Janelsins MC , TejaniMA, KamenC, PeoplesAR, MustianKM, MorrowGR. Current pharmacotherapy for chemotherapy-induced nausea and vomiting in cancer patients. Expert Opin. Pharmacother.14(6), 757–766 (2013).
   PubMed Web of Science ®Google Scholar
• Sommariva S , PongiglioneB, TarriconeR. Impact of chemotherapy-induced nausea and vomiting on health-related quality of life and resource utilization: a systematic review. Crit. Rev. Oncol. Hematol.99, 13–36 (2016).
   PubMed Web of Science ®Google Scholar
• Shih TYC , XuY, EltingLS. Costs of uncontrolled chemotherapy-induced nausea and vomiting among working-age cancer patients receiving highly or moderately emetogenic chemotherapy. Cancer110(3), 678–685 (2007).
   PubMed Web of Science ®Google Scholar
• Burke TA , WisniewskiT, ErnstFR. Resource utilization and costs associated with chemotherapy-induced nausea and vomiting (CINV) following highly or moderately emetogenic chemotherapy administered in the US outpatient hospital setting. Support. Care Cancer19(1), 131–140 (2011).
   PubMed Web of Science ®Google Scholar
• Schwartzberg L , HarrowB, LalLS, RadtchenkoJ, LymanGH. Resource utilization for chemotherapy-induced nausea and vomiting events in patients with solid tumors treated with antiemetic regimens. Am. Health Drug Benefits8(5), 273–282 (2015).
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network . NCCN Clinical Practice Guidelines in Oncology: Antiemesis–v2.2017 (2017).
   Google Scholar
• Herrstedt J , RoilaF, WarrDet al. 2016 Updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following high emetic risk chemotherapy. Support. Care Cancer25(1), 277–288 (2017).
   PubMed Web of Science ®Google Scholar
• Hesketh PJ , KrisMG, BaschEet al. Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update. J. Clin. Oncol.35(28), 3240–3261 (2017).
   PubMed Web of Science ®Google Scholar
• Roila F , WarrD, HeskethPJet al. 2016 updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following moderately emetogenic chemotherapy. Support. Care Cancer25(1), 289–294 (2017).
   PubMed Web of Science ®Google Scholar
• Ottoboni T , GelderMS, O’BoyleE. Biochronomer technology and the development of APF530, a sustained release formulation of granisetron. J. Exp. Pharmacol.6, 15–21 (2014).
   PubMedGoogle Scholar
• Gabrail N , YanagiharaR, SpaczynskiMet al. Pharmacokinetics, safety, and efficacy of APF530 (extended-release granisetron) in patients receiving moderately or highly emetogenic chemotherapy: results of two Phase II trials. Cancer Manag. Res.7, 83–92 (2015).
   PubMed Web of Science ®Google Scholar
• Raftopoulos H , BocciaR, CooperW, O’BoyleE, GrallaRJ. Slow-release granisetron (APF530) versus palonosetron for chemotherapy-induced nausea/vomiting: analysis by American Society of Clinical Oncology emetogenicity criteria. Future Oncol.11(18), 1–11 (2015).
   Web of Science ®Google Scholar
• Raftopoulos H , CooperW, O’BoyleE, GabrailN, BocciaR, GrallaRJ. Comparison of an extended-release formulation of granisetron (APF530) versus palonosetron for the prevention of chemotherapy-induced nausea and vomiting associated with moderately or highly emetogenic chemotherapy: results of a prospective, randomized, double-blind, noninferiority Phase 3 trial. Support. Care Cancer23(3), 723–732 (2015).
   PubMed Web of Science ®Google Scholar
• Schnadig ID , AgajanianR, DakhilSRet al. APF530 (granisetron inj extended-release) in a three-drug regimen for delayed CINV in highly emetogenic chemotherapy. Future Oncol.12(12), 1469–1481 (2016).
   PubMed Web of Science ®Google Scholar
• Sustol (granisetron) extended-release injection, for subcutaneous use, prescribing information . Heron Therapeutics, CA, USA (2016). www.fda.gov/downloads/Drugs/DrugSafety/UCM524796.pdf
   Google Scholar
• Navari RM . Treatment of breakthrough and refractory chemotherapy-induced nausea and vomiting. Biomed. Res. Int. 2015, 595894 (2015).
   PubMed Web of Science ®Google Scholar
• Roeland E , MaJ, BinderGet al. Hospitalization costs for nausea and vomiting: a savings opportunity. J. Clin. Oncol.35(Suppl. 31S), Abstract 155 (2017).
   Google Scholar